南新制药（688189）7月31日主力资金净流入3168.64万元

Group 1 - The core viewpoint of the news is that Nanjing New Pharmaceutical Co., Ltd. has experienced a significant stock price increase of 20.03% as of July 31, 2025, closing at 17.14 yuan, despite a substantial decline in its financial performance [1] - The company reported total revenue of 40.62 million yuan for Q1 2025, a year-on-year decrease of 70.21%, and a net profit attributable to shareholders of 8.03 million yuan, down 143.66% year-on-year [1] - The company's liquidity ratios are strong, with a current ratio of 2.250 and a quick ratio of 2.089, while the debt-to-asset ratio stands at 28.21% [1] Group 2 - Nanjing New Pharmaceutical has made investments in 6 companies and participated in 15 bidding projects, indicating active engagement in business expansion [2] - The company holds 3 trademark registrations and 27 patents, showcasing its commitment to intellectual property development [2] - Additionally, the company possesses 11 administrative licenses, reflecting its compliance and operational capabilities [2]